Could a cholesterol drug boost liver cancer treatment?
NCT ID NCT01903694
First seen Feb 12, 2026 · Last updated May 22, 2026 · Updated 15 times
Summary
This study tested whether adding the cholesterol-lowering drug pravastatin to the standard cancer drug sorafenib helps people with advanced liver cancer live longer. It involved 474 adults with Child-Pugh A cirrhosis who could not have curative treatments. The goal was to see if the combination improved survival, slowed cancer growth, and maintained quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILD-PUGH A HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Dijon
Dijon, 21079, France
Conditions
Explore the condition pages connected to this study.